Revvity falls on forecasting 2025 revenue, profit below estimates

Revvity

31/01/2025 15:04

** Shares of medical equipment maker Revvity  RVTY.N  fall
2.4% to $123.75
    ** Co forecast 2025 profit and revenue below estimates
    ** Co forecast 2025 adj. profit to be in the range of $4.90
to $5.00 per share, compared with analysts' estimates of $4.99,
as per data compiled by LSEG
    ** Forecast 2025 revenue to be in the range of $2.80 bln to
$2.85 bln, lower than estimates of $2.87 bln 
    ** RVTY was expected to forecast lower with both Danaher
 DHR.N  and Thermo Fisher  TMO.N  guiding lower vs. the Street
expectations, brokerage Leerink Partners says
    ** Adds, "thus we see limited downside surprise" as the
outlook is still 4% organic growth at the midpoint, which is
higher vs. peers so far
    ** Co, however, beats Q4 profit and revenue estimates on
strong sales in its life sciences and diagnostics units
    ** Reports Q4 adj. profit of $1.42 per share vs estimates of
$1.37 per share 
    ** Stock had risen 2.1% in 2024

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))